Prostate Cancer Mortality Lowest With Radical Prostatectomy
In a study with a follow-up period of 18 years, men treated with any other modality but radical prostatectomy had higher prostate cancer death risks.
Prostate Cancer
TRT Speeds Potency Recovery After Prostate Surgery
In a study, all men who received testosterone replacement therapy within 1 year of robot-assisted radical prostatectomy had full potency recovery at 24 months.
TRT Reduces Post-RARP Recurrence Risk in Low-Risk Prostate Cancer
Testosterone replacement therapy prolonged time to disease progression among men who underwent radical surgery for localized prostate cancer.
Intense ADT Prior to RP May Improve Outcomes in Locally Advanced PCa
A phase 2 study demonstrated higher rates of pathologic complete response or minimal residual disease.
Long-Term Use of Low-Dose Aspirin May Lower PCa Mortality
A population-based study found no effect of low-dose aspirin use within 1 year of diagnosis on prostate cancer death risk.
Time from Definitive Therapy to ADT Predicts mCRPC Risk
Time from definitive therapy for localized prostate cancer to the start of androgen deprivation therapy (ADT) independently predicts the risk of metastatic castration-resistant prostate cancer (mCRPC) and death, a new study suggests. The study, led by Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake City, included 253…
Prostate Cancer Risk After Single Negative Biopsy Quantified
Almost one quarter of men who have a single negative prostate biopsy are eventually diagnosed with prostate cancer (PCa) within 20 years, according to investigators. The finding is from a study of 95,675 men who had a negative first transrectal ultrasound (TRUS)-guided prostate biopsy from January 1994 to October 2014. The 5-, 10-, 15, and…
First-Year Post-ADT Weight Loss Predicts Higher PCa Death Risk
Weight loss in the first year after starting androgen deprivation therapy in men who have undergone radical surgery for prostate cancer ups the risk of metastatic disease and death from prostate cancer.
Longer Androgen Suppression With RT Superior for Advanced PCa
Study finds 18 vs 6 months of androgen suppression and radiotherapy for locally advanced prostate cancer is associated with a 30% decreased risk of death from the disease.
Adding Docetaxel to ADT Not Beneficial in High-Risk PCa
In a study of men with nonmetastatic high-risk prostate cancer who have rising PSA after primary therapy, investigators found no significant difference in PSA progression-free survival.
Next post in Prostate Cancer
